Combined Antioxidant Therapy on Oxidative Stress, Mitochondrial Dysfunction Markers in Diabetic Retinopathy
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The present study aims to support previous research on antioxidant therapy effects in
diabetic retinopathy outcome. The investigators intend to assess 180 patients with diabetic
retinopathy in different stages (moderate, severe and proliferative), whom either will be
assigned to placebo group or combined antioxidant therapy. Each group will receive the
intervention for 12 months. Such intervention consists in taking one tablet (placebo or
antioxidant therapy) orally, a day.
At baseline, blood and urine samples will be collected in order to assess metabolic and
oxidative stress status, mitochondrial function or dysfunction, liver and kidney function. In
addition, fluorescein angiography will be done for the categorization of diabetic
retinopathy. After six months and at the end of the intervention, blood and urine
measurements as well as angiographies will be done for comparing the outcomes between both
groups and correlate oxidative stress status, mitochondrial dysfunction with grade of
retinopathy.